<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) and catastrophic <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (CAPS) can be challenging to treat </plain></SENT>
<SENT sid="1" pm="."><plain>As they are rare, clinicians are not often exposed to these complex diseases </plain></SENT>
<SENT sid="2" pm="."><plain>For the patient resistant to standard treatments new therapeutic directions can be perplexing, especially in the context of ongoing thromboses and <z:mp ids='MP_0001914'>bleeding</z:mp> episodes </plain></SENT>
<SENT sid="3" pm="."><plain>We describe 3 patients, 2 with APS and one with CAPS, resistant to conventional medications, who responded to treatment with rituximab, an anti-CD20 monoclonal antibody </plain></SENT>
<SENT sid="4" pm="."><plain>Since rituximab infusion, <z:hpo ids='HP_0000001'>all</z:hpo> the patients have had stable platelet counts and no further episodes of <z:mp ids='MP_0001914'>bleeding</z:mp> or thromboses </plain></SENT>
</text></document>